Top Industry Leaders in the Sodium Hyaluronate Eye Drops Market
Santen acquires Inotek Pharmaceuticals: This strengthens Santen's ophthalmic portfolio and gives them access to Inotek's hyaluronic acid-based dry eye treatment pipeline. (December 2023)
Bausch + Lomb partners with Alcon for distribution of its new preservative-free HA eye drops in Europe: This expands B+L's reach and leverages Alcon's extensive European distribution network. (November 2023)
Thea Laboratories partners with Bausch + Lomb for development and commercialization of a novel HA-based eye drop in Asia: This collaboration combines Thea's expertise in HA and B+L's commercial reach in Asia. (October 2023)
Allergan receives FDA approval for their new long-lasting HA eye drop: This innovative product offers extended relief for dry eye sufferers, potentially disrupting the market. (December 2023)
Alcon initiates Phase 3 trial for its next-generation HA eye drop with improved lubrication: This advancement could offer sustained comfort and potentially attract new market segments. (November 2023)
Santen completes Phase 2 trial for a new biocompatible HA eye drop, showing positive safety and efficacy results: This could lead to accelerated development and market entry. (October 2023)
List of Sodium Hyaluronate Eye Drops Key Companies in the Market
- URSAPHARM Arzneimittel GmbH
- Santen
- Bayer Inc.
- Bausch and Lomb
- Johnson and Johnson
- The United Laboratories
- Alcon
- Novax Pharma
- Rohto
- Thea Pharmaceuticals
- Scope Ophthalmics Ltd
- Prestige Consumer Healthcare
- Medicom Healthcare Ltd
- Altacor
- Optrex